<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6585">
  <stage>Registered</stage>
  <submitdate>27/06/2017</submitdate>
  <approvaldate>27/06/2017</approvaldate>
  <nctid>NCT03201965</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis</studytitle>
    <scientifictitle>A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-001737-27</secondaryid>
    <secondaryid>CR108193</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Amyloidosis</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Cyclophosphamide
Treatment: drugs - Bortezomib
Treatment: drugs - Dexamethasone, 40 mg
Treatment: drugs - Daratumumab

Active Comparator: CyBorD alone (cyclophosphamide/bortezomib/dexamethasone) - Participants will receive dexamethasone (40 milligrams [mg] orally or intravenous [IV] dose), followed by cyclophosphamide (300 milligram per meter square [mg/m^2] orally or IV dose), then bortezomib (1.3 mg/m^2 subcutaneous injection) weekly on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles.

Experimental: CyBorD plus Daratumumab - Participants will receive dexamethasone (20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing) followed by 1800 mg of daratumumab subcutaneously followed by cyclophosphamide (300 mg/m^2 orally or IV dose weekly) and bortezomib (1.3 mg/m^2 subcutaneous injection weekly) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 2 years.


Treatment: drugs: Cyclophosphamide
Participants will receive 300 mg/m^2 of cyclophosphamide as an oral or IV dose.

Treatment: drugs: Bortezomib
Participants will receive 1.3 mg/m^2 of bortezomib as an subcutaneous (SC) injection.

Treatment: drugs: Dexamethasone, 40 mg
Participants of CyBorD alone arm will receive 40 mg dexamethasone orally or IV dose. Participants of CyBorD plus daratumumab arm will receive dexamethasone 20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing to make a total of 40 mg.

Treatment: drugs: Daratumumab
Participants will receive 1800 mg of daratumumab subcutaneously.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of Participants With Overall Complete Hematologic Response - Overall complete hematologic response rate will be defined as percentage of participants who achieve Complete Hematologic Response (CHR), according to the International Amyloidosis Consensus Criteria. CHR: normalization of free light chain levels and ratio, negative serum and urine immunofixation.</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Major Organ Deterioration Progression-Free Survival (MOD-PFS) - Major Organ Deterioration Progression-Free Survival (MOD-PFS) is defined from randomization to any one of following events, whichever comes first: death; clinical manifestation of cardiac/renal failure; development of hematologic progression of disease. Clinical manifestation of cardiac failure: development of dyspnea at rest (for at least 3 consecutive days) and due solely to amyloidosis cardiac deterioration, or need for cardiac transplant, left ventricular assist device, or intraaortic balloon pump or clinical manifestation of renal failure: development of end stage renal disease (need for hemodialysis or renal transplant). Hematologic progression of disease: from CHR, any detectable monoclonal protein or abnormal free light chain ratio (light chain must be double), from PR, 50% increase in serum M-protein to &gt; 0.5 gram per deciliter [g/dL] or 50% increase in urine M-protein to &gt; 200 milligram per day [mg/day]; free light chain increase of 50% to &gt; 100 mg/L.</outcome>
      <timepoint>Approximately 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-Free Survival (PFS) - Progression-free survival (PFS) is defined as time from date of randomization to date of first documentation of hematologic disease progression, or organ (cardiac, renal, or liver) progression, or death due to any cause, whichever occurs first. Hematologic disease progression: from CHR, any detectable monoclonal protein or abnormal free light chain ratio (light chain must be double), from PR, 50% increase in serum M-protein to &gt; 0.5 g/dL or 50% increase in urine M-protein to &gt; 200 mg/day; free light chain increase of 50% to &gt; 100 mg/L. Organ progression for heart: NT-proBNP progression [&gt; 30%; &gt; 300 ng/l increase] or cardiac troponin (cTn) progression [greater than or equal to (&gt;=) 33% increase] or ejection fraction progression [&gt;= 10% decrease]; for kidney: 50% increase (at least 1 gram per day [g/day]) of 24-hour urine protein to &gt; 1 g/day or 25% worsening of serum creatinine or creatinine clearance; for liver: 50% increase of alkaline phosphatase above lowest value).</outcome>
      <timepoint>Approximately 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Organ Response Rate (OrRR) - Organ response rate (OrRR) for kidney, heart, liver is defined as the proportion of baseline organ involved participants who achieve organ response in each corresponding organ. Organ response defined for heart :N-terminal brain pronatriuretic peptide (NT-proBNP) response (&gt; 30% and &gt; 300 nanogram per liter [ng/L] decrease in participants with baseline NT-proBNP &gt;= 650 ng/L) or New York Heart Association (NYHA) class response (&gt;= 2 class decrease in participants with baseline NYHA class 3 or 4); for kidney: 50% decrease (at least 0.5 grams per day [g/day]) of 24 hour urine protein (urine protein must be &gt; 0.5 g/day pretreatment). Creatinine and creatinine clearance must not worsen by 25% over baseline; for liver: 50% decrease in abnormal alkaline phosphatase value.</outcome>
      <timepoint>Approximately 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS) - Overall survival (OS) is measured from the date of randomization to the date of the participant's death.</outcome>
      <timepoint>Approximately 8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Fatigue Scale Score - The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).</outcome>
      <timepoint>Baseline, up to end of study (approximately 5 years)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in the SF-36v2 Mental Component Summary (MCS) - The SF-36 is a survey of participant health. It consists of 8 individual domains, which are weighted sums of the questions in their section. The 8 domains are: vitality (VT), physical functioning (PF), bodily pain (BP), general health (GH), Role-Physical (RP), Role-Emotional (RE), social functioning (SF) and mental health (MH). Each of these 8 scales (domains) is scored from 0 to 100 with higher scores indicating better health. Based on the scale scores, the summary mental component score (MCS) is derived. Scales contributing most to the scoring of the SF-36 MCS include the VT, SF, RE and MH. Other domains not noted contribute to the scoring but to a lesser degree. The scoring is derived based on an algorithm that has been developed in a software provided by the developer. The summary MCS score is also scaled from 0 to 100 with higher scores indicating better health.</outcome>
      <timepoint>Baseline, up to end of study (approximately 5 years)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in the EORTC QLQ-C30 Global Health Status Scale Score - The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement.</outcome>
      <timepoint>Baseline, up to end of study (approximately 5 years)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Next Treatment (TNT) - Time to next treatment (TNT) defined as the time from the date of randomization to the start date of subsequent treatment for AL amyloidosis.</outcome>
      <timepoint>Approximately 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hematologic Very Good Partial Response or Better Rate - Hematologic very good partial response or better rate is defined as the percentage of participants who achieve hematologic complete response or very good partial response. Complete response: normalization of free light chain levels and ratio, negative serum and urine immunofixation; Very good partial response: reduction in the dFLC less than 40 mg/L.</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Complete Hematologic Response - Time to complete hematologic response is defined as the time between the date of randomization and the first efficacy evaluation at which the participant has met the criteria for hematologic complete response.</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Hematologic Very Good Partial Response (VGPR) or Better Response - Time to hematologic VGPR or better response is defined as the time between the date of randomization and the first efficacy evaluation at which the participant has met the criteria for hematologic VGPR or better response.</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Complete Hematologic Response - Duration of complete hematologic response is defined as the time between the date of initial documentation of complete hematologic response to the date of first documented evidence of hematologic progressive disease.</outcome>
      <timepoint>Approximately 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Hematologic Very Good Partial Response (VGPR) or Better Response - Duration of hematologic VGPR or better response is defined as the time between the date of initial documentation of hematologic VGPR or better response to the date of first documented evidence of hematologic progressive disease.</outcome>
      <timepoint>Approximately 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Organ Response - Time to organ response is defined as the time between the date of randomization and the first efficacy evaluation at which the participant has each corresponding organ response.</outcome>
      <timepoint>Approximately 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Organ Response - Duration of organ response is defined as the time between the date of initial documentation of each corresponding organ response to the date of first documented evidence of the corresponding organ progressive disease.</outcome>
      <timepoint>Approximately 5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histopathological diagnosis of amyloidosis based on detection by immunohistochemistry
             and polarizing light microscopy of green bi-refringent material in congo red stained
             tissue specimens (in an organ other than bone marrow) or characteristic electron
             microscopy appearance

          -  Measurable disease of amyloid light-chain (AL) amyloidosis as defined by at least one
             of the following:

               1. serum monoclonal protein greater than or equal (&gt;=) to 0.5 grams/deciliter (g/dL)
                  by protein electrophoresis (routine serum protein electrophoresis and
                  immunofixation performed at central lab)

               2. serum free light chain greater than or equal to (&gt;=) 5.0 milligram/deciliter
                  (mg/dL) with an abnormal kappa:lambda ratio or the difference between involved
                  and uninvolved free light chains (dFLC) &gt;= 5 mg/ dL

          -  One or more organs impacted by AL amyloidosis according to consensus guidelines

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior therapy for AL amyloidosis or multiple myeloma including medications that target
             CD38, with the exception of 160 mg dexamethasone (or equivalent corticosteroid)
             maximum exposure prior to randomization

          -  Previous or current diagnosis of symptomatic multiple myeloma, including the presence
             of lytic bone disease, plasmacytomas, &gt;= 60 percent (%) plasma cells in the bone
             marrow, or hypercalcemia

          -  Evidence of significant cardiovascular conditions as specified below:

               1. NT-ProBNP &gt; 8500 nanogram per liter (ng/L)

               2. New York Heart Association (NYHA) classification IIIB or IV heart failure

               3. Heart failure that in the opinion of the investigator is on the basis of ischemic
                  heart disease (eg, prior myocardial infarction with documented history of cardiac
                  enzyme elevation and electrocardiogram [ECG] changes) or uncorrected valvular
                  disease and not primarily due to AL amyloid cardiomyopathy

               4. Inpatient admission to a hospital for unstable angina or myocardial infarction
                  within the last 6 months prior to first dose or percutaneous cardiac intervention
                  with recent stent within 6 months or coronary artery bypass grafting within 6
                  months

               5. For participants with congestive heart failure, cardiovascular-related
                  hospitalizations within 4 weeks prior to randomization

               6. Participants with a history of sustained ventricular tachycardia or aborted
                  ventricular fibrillation or with a history of atrioventricular (AV) nodal or
                  sinoatrial (SA) nodal dysfunction for which a pacemaker/implantable
                  cardioverter-defibrillators [ICD] is indicated but not placed (participants who
                  do have a pacemaker/ICD are allowed on study)

               7. Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's
                  formula (QTcF) &gt; 500 milliseconds (msec). Participants who have a pacemaker may
                  be included regardless of calculated QTc interval

               8. Supine systolic blood pressure &lt; 90 millimeter of mercury (mmHg), or symptomatic
                  orthostatic hypotension, defined as a decrease in systolic blood pressure upon
                  standing of &gt; 20 mmHg despite medical management (eg, midodrine,
                  fludrocortisones) in the absence of volume depletion

          -  Planned stem cell transplant during the first 6 cycles of protocol therapy are
             excluded. Stem cell collection during the first 6 cycles of protocol therapy is
             permitted

          -  Seropositive for human immunodeficiency virus (HIV)

          -  Known to have hepatitis B surface antigen positivity, or known to have a history of
             hepatitis C

          -  Grade 2 sensory or Grade 1 painful peripheral neuropathy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>5/10/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>370</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/10/2025</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <postcode>3128 - Box Hill</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Kortrijk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>D체sseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>T체bingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>W체rzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Den Haag</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Veldhoven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Badalona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Granada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Leon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Pamplona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Salamanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>San Crist처bal De La Laguna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Boras</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Lund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uppsala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Antalya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Atakum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Talas</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Janssen Research &amp; Development, LLC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the efficacy and safety of daratumumab plus
      cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in
      treatment of newly diagnosed AL amyloidosis participants.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03201965</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Janssen Research &amp; Development, LLC Clinical Trial</name>
      <address>Janssen Research &amp; Development, LLC</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Study contact</name>
      <address />
      <phone>844-434-4210</phone>
      <fax />
      <email>JNJ.CT@sylogent.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>